A study of VY-SOD101 for a treatment of monogenic form of Amyotrophic lateral sclerosis (ALS)

Trial Profile

A study of VY-SOD101 for a treatment of monogenic form of Amyotrophic lateral sclerosis (ALS)

Planning
Phase of Trial: Phase I

Latest Information Update: 20 May 2016

At a glance

  • Drugs VY SOD101 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 20 May 2016 New trial record
    • 12 May 2016 According to a Voyager Therapeutics media release, the company expects to file an Investigational New Drug (IND) application for VY-SOD101 in late 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top